Edition:
United Kingdom

MiMedx Group Inc (MDXG.OQ)

MDXG.OQ on NASDAQ Stock Exchange Capital Market

12.50USD
15 Dec 2017
Change (% chg)

$0.36 (+2.97%)
Prev Close
$12.14
Open
$12.17
Day's High
$13.07
Day's Low
$12.04
Volume
4,336,704
Avg. Vol
714,060
52-wk High
$17.47
52-wk Low
$7.64

Chart for

About

MiMedx Group, Inc. is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone. The Company's Regenerative Biomaterials segment includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical,... (more)

Overall

Beta: 0.89
Market Cap(Mil.): $1,364.26
Shares Outstanding(Mil.): 112.47
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.01 10.62
ROE: -- 16.85 14.20

BRIEF-MiMedx Forecasts 2018 Revenue To Be In Range Of $383 Mln To $387 Mln

* MIMEDX FORECASTS 2018 REVENUE TO BE IN THE RANGE OF $383 MILLION TO $387 MILLION

13 Dec 2017

BRIEF-MiMedx Says It Expects To Exceed Top End Of Q4 Revenue Guidance Of $88 Mln

* MIMEDX ANNOUNCES EXPECTATION TO EXCEED TOP END OF FOURTH QUARTER REVENUE GUIDANCE OF $88 MILLION

30 Nov 2017

BRIEF-Mimedx provides update on its reimbursement coverage

* Mimedx Group Inc - ‍provided a reimbursement update in light of FDA final and draft guidance documents related to human tissue​

21 Nov 2017

BRIEF-MiMedx Group sees FY 2017 revenue $320.6 million to $321.6 million

* MiMedx Group Inc - ‍reiterates Q4 and full year 2017 guidance​

17 Nov 2017

BRIEF-MiMedx announces Q3 2017 results

* MiMedx announces record results for third quarter of 2017 and raises full year revenue guidance

26 Oct 2017

BRIEF-Mimedx Group Inc preliminary Q3 revenue $84.6 million

* Announces third quarter revenues of $84.6 million exceeds guidance by more than 5 percent

10 Oct 2017

BRIEF-MiMedx board authorizes $10 mln increase to share repurchase program

* MiMedx board of directors authorizes $10 million increase to the company's share repurchase program

09 Oct 2017

BRIEF-MIMEDX GROUP REAFFIRMS REVENUE EXPECTATIONS FOR Q3

* DR. GLORIA MATTHEWS JOINS MIMEDX AS ITS SENIOR VICE PRESIDENT OF RESEARCH AND DEVELOPMENT

03 Oct 2017

BRIEF-Court sets trial date for MiMedx patent infringement lawsuit

* Court sets the trial date for MiMedx patent infringement lawsuit against MTF, Medline and Liventa

02 Oct 2017

BRIEF-MiMedx agrees to lawsuit settlement with terminated employee

* MiMedx agrees to lawsuit settlement with terminated employee

26 Sep 2017

Competitors

  Price Chg
Shire PLC (SHP.L) 3,762.50 +77.50
Shire PLC (3159084.L) -- --
Smith & Nephew plc (SN.L) 1,282.00 -6.00

Earnings vs. Estimates